Table 1. Summary of the eight included studies.
| First author, (year) |
Extent/ Phase |
No. of patients |
Treatment arms | RR | HR for LRC (95% CI) |
mPFS (mo) | HR for PFS (95% CI) |
mOS (mo) |
HR for OS (95% CI) |
Grade 3/4 toxicity (con. vs exp. %) |
Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Concurrent chemoradiotherapy vs. radiotherapy + an anti-EGFR agent | |||||||||||
| Lefebvre (2013) |
LA II |
69 | Docetaxel 75 mg/m2) + cisplatin (75 mg/m2) + 5-FU (750 mg/m2, d1-5) (#3) → RT (70 Gy) with cisplatin (100 mg/m2, #3 q3wks) | NA | NA | NR | 0.81 (0.50–1.31) | NR | 0.93 (0.41–2.07) P = ns |
Skin toxicity (26 vs 57) | 3 |
| 56 | Docetaxel + cisplatin + 5-FU (same, #3) → RT (70 Gy) with cetuximab (400 mg/m2 -> 250 mg/m2), wkly) | NA | NR | NR | |||||||
| Giralt (2015) |
LA II |
61 | RT (70-72 Gy) with cisplatin (100 mg/m2, #2 q3 wks | NA | 1.61 (0.98–2.66) P = 0.06 |
NR | 1.73 (1.07–2.81) P = 0.03 |
NR | 1.59 (0.91–2.79) P = 0.10 |
Skin injury (11 vs 24) Odynophagia (19 vs 8) Stomitis (5 vs 16) Dermatitis (0 vs 17) |
3 |
| 90 | RT (70-72 Gy) with panitumumab (9 mg/kg (#3 q3 wks) | NA | NA | NA | |||||||
| Magrini (2016) |
LA II |
35 | RT (70 Gy) with cisplatin (40 mg//m2, wkly) | NA | 1.76 (0.69–4.47) P = ns |
NR | NA | NR | 1.85 (0.60–5.67) P = ns |
Skin toxicity (44 vs 21) | 3 |
| 35 | RT (70 Gy) with cetuximab (400 mg/m2 -> 250 mg/m2, wkly) |
NA | NR | NR | |||||||
| Concurrent chemoradiotherapy vs. concurrent chemoradiotherapy + an anti-EGFR agent | |||||||||||
| Martins (2013) |
LA II |
105 | RT (70 Gy) with cisplatin ((100 mg/m2, #3 q3wks) | 40% | NA | NR | 0.90 P = 0.71 |
18.9 | 1.05 P = 0.88 |
NA | 3 |
| 99 | RT (70 Gy) with cisplatin + erlotinib (150 mg/day) | 52% | NR | 18.9 | |||||||
| Ang (2014) |
LA III |
417 | Accelerated RT (70-72 Gy) with cisplatin (100 mg/m2, #3 q3wks) | NA | 1.30 (0.99–1.70) P = 0.97 |
NR | 1.08 (0.88–1.32) P = 0.76 |
NR | 0.95 (0.74–1.21) P = 0.32 |
Mucositis (7 vs 10) Skin reaction (< 1 vs 4.5) |
3 |
| 444 | Accelerated RT (70-72 Gy) with cisplatin (same) + cetuximab (400 mg/m2 -> 250 mg/m2, wkly) | NA | NR | NR | |||||||
| Mesia (2015) |
LA II |
63 | RT (70 Gy) with cisplatin (100 mg/m2), #3 q3wks) | 51% | 1.33 (0.77–2.30) P = 0.31 |
1.15 (0.68–1.96) P = 0.61 |
1.63 (0.88–3.02) P = 0.12 |
Dermatitis (0 v 7) Skin injury (13 v 31) Mucositis 24 v 55) |
3 | ||
| 87 | RT (70 Gy) with cisplatin (75 mg/m2) + panitumuab (9.0 mg/kg) (#3 q3wks) | 62% | |||||||||
| Lee (2015) |
LA II |
34 | Docetaxel (75 mg/m2) + cisplatin (75 mg/m2 (#3 q3wks) → RT with cisplatin (30 mg/m2, wkly) |
NA | NA | NA | 0.66 (0.25–1.72) P = 0.359 |
NA | 0.59 (0.17–2.01) P = 0.313 |
Mucositis (9 v 26) Skin toxicity (3 v 11) Odynophagia (11 v 20) |
3 |
| 32 | Docetaxel (same) + cisplatin (same) + cetuximab (400 mg/m2 -> 250 mg/m2, weekly) → RT with cisplatin (30 mg/m2, wkly) + cetuximab (250 mg/m2, wkly) | NA | NA | NA | |||||||
| Eriksen (2014) |
LA III |
309 | Accelerated RT (66-68 Gy) with cisplatin (40 mg/m2, wkly) | NA | 0.8 (0.6–1.2) | NA | 1.0 (0.7–1.7) | NA | 0.9 (0.6–1.3) | NA | 3 |
| 310 | Accelerated RT (66-68 Gy) with cisplatin (same) + zalutumumab (8 mg/kg, wkly) | NA | NA | NA | |||||||
LA, locoregionally advanced; #, cycles; wkly, weekly; q3wks, every 3 weeks; EGFR, epidermal growth factor receptor; cot., control; exp., experimental; RT, radiotherapy; RR, response rate; LRC, locoregional control; HR, hazard ratio; CI, confidence interval; mPFS, median progression-free survival; mOS, median overall survival; mo, months; NR, not reached; NA, not available.